Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep;80(9):1295-1304.
doi: 10.1007/s00228-024-03702-9. Epub 2024 May 27.

Population pharmacokinetics and dosage optimization of linezolid in Chinese older patients

Yuanchen Li  1 , Qiu Fang  2 , Zejun Wu  3 , Siqi Huang  2 , Weihong Ge  3   4 , Jizhong Shen  5   6 , Huaijun Zhu  7   8
Affiliations

Population pharmacokinetics and dosage optimization of linezolid in Chinese older patients

Yuanchen Li et al. Eur J Clin Pharmacol. 2024 Sep.

Abstract

Purpose: To assess the pharmacokinetics and pharmacodynamics of linezolid in a retrospective cohort of hospitalized Chinese older patients.

Methods: Patients > 60 years of age, who received intravenous linezolid (600 mg), were included. A population pharmacokinetics (PPK) model was established using nonlinear mixed-effects modeling. The predictive performance of the final model was assessed using goodness-of-fit plots, bootstrap analyses, and visual predictive checks. Monte Carlo simulations were used to evaluate the achievement of a pharmacodynamics target for the area under the serum concentration-time curve/minimum inhibitory concentration (AUC0-24/MIC).

Results: A total of 210 samples were collected from 120 patients. A one-compartment PPK model with linear elimination best predicted the linezolid plasma concentrations. Linezolid clearance (CL) was 4.22 L h-1 and volume of distribution (Vd) was 45.80 L; serum uric acid (SUA) was a significant covariate of CL.

Conclusion: The results of this study indicated that the standard dose was associated with a risk of overexposure in older patients, particularly those with high SUA values; these patients would benefit from a lower dose (300 mg every 12 h).

Keywords: Dose optimization; Linezolid; Older patients; Population pharmacokinetics.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Stalker DJ, Jungbluth GL (2003) Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet 42:1129–1140. https://doi.org/10.2165/00003088-200342130-00004 - DOI - PubMed
    1. Beringer P, Nguyen M, Hoem N et al (2005) Absolute bioavailability and pharmacokinetics of linezolid in hospitalized patients given enteral feedings. Antimicrob Agents Chemother 49(9):3676–3681. https://doi.org/10.1128/AAC.49.9.3676-3681.2005 - DOI - PubMed - PMC
    1. Rybak MJ, Hershberger E, Moldovan T, Grucz RG (2000) In vitro activities of daptomycin, Vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including Vancomycin- intermediate and -resistant strains. Antimicrob Agents Chemother 44:1062–1066. https://doi.org/10.1128/AAC.44.4.1062-1066.2000 - DOI - PubMed - PMC
    1. Conradie F, Bagdasaryan TR, Borisov S et al (2022) Bedaquiline-pretomanid-linezolid regimens for drug-resistant tuberculosis. N Engl J Med 387:810–823. https://doi.org/10.1056/NEJMoa2119430 - DOI - PubMed - PMC
    1. Singh B, Cocker D, Ryan H, Sloan DJ (2019) Linezolid for drug-resistant pulmonary tuberculosis. Cochrane Database Syst Rev 3:CD012836. https://doi.org/10.1002/14651858.CD012836.pub2 - DOI - PubMed

MeSH terms

LinkOut - more resources